Targeting blood-brain barrier changes during inflammatory pain: An opportunity for optimizing CNS drug delivery

Therapeutic Delivery

Volumn 2, Issue 8, 2011, Pages 1015-1041

  Ronaldson, Patrick T ^a   Davis, Thomas P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACTIVIN RECEPTOR LIKE KINASE 1; ALFENTANIL; BREAST CANCER RESISTANCE PROTEIN; BUPRENORPHINE; CLAUDIN; CODEINE; DEXAMETHASONE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; GLYCOPROTEIN P; MEMBRANE ASSOCIATED GUANYLATE CYCLASE KINASE; METHADONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORBUPRENORPHINE; OCCLUDIN; ORGANIC ANION TRANSPORTER; OXYCODONE; PARACETAMOL; PRAVASTATIN; PROTEIN ZO1; PROTEIN ZO2; SUFENTANIL; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ANTINOCICEPTION; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN MICROCIRCULATION; CEREBROSPINAL FLUID; CHRONIC INFLAMMATION; CHRONIC PAIN; CONSTIPATION; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INFLAMMATORY PAIN; MICROVASCULAR ENDOTHELIAL CELL; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PERIPHERAL INFLAMMATORY PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; TIGHT JUNCTION; VASCULAR ENDOTHELIUM; VOMITING;

EID: 79961195196     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.67     Document Type: Review

References (268)

1. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol. Interv. 10(5), 293-304 (2010).
2. Hau VS, Huber JD, Campos CR, Davis RT, Davis TP. Effect of lambda-carrageenan-induced infammatory pain on brain uptake of codeine and antinociception. Brain Res. 1018(2), 257-264 (2004). (Pubitemid 38992827)
3. Seelbach MJ, Brooks TA, Egleton RD, Davis TP. Peripheral infammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J. Neurochem. 102(5), 1677-1690 (2007). (Pubitemid 47256196)
4. McCaffrey G, Seelbach MJ, Staatz WD et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral infammatory hyperalgesia. J. Neurochem. 106(6), 2395-2409 (2008).
5. McCaffrey G, Willis CL, Staatz WD et al. Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J. Neurochem. 110(1), 58-71 (2009).
6. Ronaldson PT, DeMarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis T P. Transforming growth factor-b signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during infammatory pain. J. Cereb. Blood Flow Metab. 29(6), 1084-1098 (2009).
7. Lochhead JJ, McCaffrey G, Quigley CE et al. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J. Cereb.Blood Flow Metab. 30(9), 1625-1636 (2010).
8. Ronaldson PT, Finch JD, DeMarco KM, Quigley CE, Davis TP. Infammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J. Pharmacol. Exp. Ther. 336(3), 827-839 (2011).
9. Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 10(3), 167-184 (2010).
10. Wolka AM, Huber JD, Davis TP. Pain and the blood-brain barrier: obstacles to drug delivery. Adv. Drug Deliv. Rev. 55(8), 987-1006 (2003). (Pubitemid 37304002)
11. Dickinson T, Mitchell R, Robberecht P, Fleetwood-Walker SM. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 38(1), 167-180 (1999). (Pubitemid 29073536)
12. Miller DB, O'Callaghan JP. Neuroendocrine aspects of the response to stress. Metabolism 51(6 Suppl. 1), 5-10 (2002). (Pubitemid 34624854)
13. Loram LC, Taylor FR, Strand KA et al. Prior exposure to glucocorticoids potentiates lipopolysaccharide induced mechanical allodynia and spinal neuroinfammation. Brain Behav. Immun. DOI: 10.1016/j. bbi.2011.04.013 (2011) (Epub ahead of print).
14. Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol. Arch. Med. Wewn. 119(7-8), 469-477 (2009).
15. Gloth FM, III. Pharmacological management of persistent pain in older persons: focus on opioids and nonopioids. J. Pain 12(3 Suppl. 1), S14-S20 (2011).
16. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 13(5), 401-435 (2010).
17. Vadivelu N, Mitra S, Hines RL. Peripheral opioid receptor agonists for analgesia: a comprehensive review. J. Opioid. Manag. 7(1), 55-68 (2011).
18. Hamabe W, Maeda T, Kiguchi N, Yamamoto C, Tokuyama S, Kishioka S. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J. Pharmacol. Sci. 105(4), 353-360 (2007).
19. Labuz D, Mousa SA, Schafer M, Stein C, Machelska H. Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res. 1160, 30-38 (2007). (Pubitemid 47061436)
20. Haas DA. An update on analgesics for the management of acute postoperative dental pain. J. Can. Dent. Assoc. 68(8), 476-482 (2002).
21. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The 'toll' of opioid-induced glial activation: improving the clinical effcacy of opioids by targeting glia. Trends Pharmacol. Sci. 30(11), 581-591 (2009).
22. Hutchinson MR, Zhang Y, Brown K et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4 (TLR4). Eur. J. Neurosci. 28(1), 20-29 (2008).
23. Ehrlich P. Das sauerstufbudurfnis des organismus. In: Eine Farbenanalytische Studie. Hirschwald (1885).
24. Ehrlich P. Ueber die beziehungen von chemischer constitution, verteilung und pharmakologischer wirkung. In: Gesammelte Arbeiten zur Immunitaetsforschung. Hischwald, 574 (1904).
25. Goldmann EE. Vitalfarbung am zentralnervensystem. Abhandl Konigl preuss Akad Wiss 1, 1-60 (1913).
26. Lewandowsky M. Zur lehre von der cerebrospinalfussigkeit. Z. Klin. Med. 40, 480-494 (1900).
27. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57(2), 173-185 (2005). (Pubitemid 41043883)
28. Tschirgi RD. Blood-brain barrier: fact or fancy? Fed. Proc. 21, 665-671 (1962).
29. Maynard EA, Schultz RL, Pease DC. Electron microscopy of the vascular bed of rat cerebral cortex. Am. J. Anat. 100(3), 409-433 (1957).
30. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34(1), 207-217 (1967).
31. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 40(3), 648-677 (1969).
32. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol. Neurobiol. 25(1), 5-23 (2005). (Pubitemid 40558582)
33. Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol. 1(5), 409-417 (1977).
34. Ose A, Kusuhara H, Yamatsugu K et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos. 36(2), 427-434 (2008). (Pubitemid 351185757)
35. Roberts LM, Black DS, Raman C et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fuid barrier by in vivo biotinylation. Neuroscience 155(2), 423-438 (2008).
36. Yousif S, Saubamea B, Cisternino S et al. Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein. J. Neurochem. 107(3), 647-657 (2008).
37. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic ana lysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, favopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther. 333(3), 788-796 (2010).
38. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58(2), 140-161 (2006).
39. Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD. Decreased blood-brain barrier permeability to fuorescein in streptozotocin-treated rats. Neurosci. Lett. 411(1), 1-5 (2007). (Pubitemid 44751936)
40. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the effux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J. Cereb. Blood Flow Metab. 28(6), 1222-1234 (2008). (Pubitemid 351733346)
41. Dauchy S, Miller F, Couraud PO et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem. Pharmacol. 77(5), 897-909 (2009).
42. Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R. Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm. Res. 24(7), 1262-1274 (2007). (Pubitemid 46870591)
43. Uchida Y, Ohtsuki S, Katsukura Y et al. Quantitative targeted absolute proteomincs of human blood-brain barrier transporters and receptors. J. Neurochem. 117(2), 333-345 (2011).
44. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW. Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinfammatory drugs. Endocrinology 150(2), 1025-1032 (2009).
45. Westholm DE, Salo DR, Viken KJ, Rumbley JN, Anderson GW. The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics. Endocrinology 150(11), 5153-5162 (2009).
46. Ose A, Kusuhara H, Endo C et al. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and effux of drugs across the blood-brain barrier. Drug Metab. Dispos. 38(1), 168-176 (2010).
47. Kusch-Poddar M, Drewe J, Fux I, Gutmann H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Res. 1064(1-2), 21-31 (2005). (Pubitemid 41774641)
48. Ose A, Ito M, Kusuhara H et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxyl ate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active effux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab. Dispos. 37(2), 315-321 (2009).
49. Miyajima M, Kusuhara H, Fujishima M, Adachi Y, Sugiyama Y. Organic anion transporter 3 mediates the effux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metab. Dispos. 39(5), 814-819 (2011).
50. Batrakova EV, Zhang Y, Li Y et al. Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier. Pharm. Res. 21(11), 1993-2000 (2004). (Pubitemid 40941218)
51. Chishty M, Begley DJ, Abbott NJ, Reichel A. Interaction of nucleoside analogues with nucleoside transporters in rat brain endothelial cells. J. Drug Target 12(5), 265-272 (2004). (Pubitemid 39294867)
52. Dogrukol-Ak D, Kumar VB, Ryerse JS et al. Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J. Cereb. Blood Flow Metab. 29(2), 411-422 (2009).
53. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune.Pharmacol. 1(3), 223-236 (2006). (Pubitemid 44244128)
54. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178-201 (2008).
55. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325(6101), 253-257 (1987). (Pubitemid 17049884)
56. Tao-Cheng JH, Nagy Z, Brightman MW. Tight junctions of brain endothelium in vitro are enhanced by astroglia. J. Neurosci. 7(10), 3293-3299 (1987).
57. Neuhaus J, Risau W, Wolburg H. Induction of blood-brain barrier characteristics in bovine brain endothelial cells by rat astroglial cells in transflter coculture. Ann. NY Acad. Sci. 633, 578-580 (1991).
58. Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 19(1), 13-26 (1997). (Pubitemid 27050446)
59. Willis CL, Nolan CC, Reith SN et al. Focal astrocyte loss is followed by microvascular damage, with subsequent repair of the blood-brain barrier in the apparent absence of direct astrocytic contact. Glia 45(4), 325-337 (2004). (Pubitemid 38332433)
60. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16(1), 1-13 (2004). (Pubitemid 38569790)
61. Goldberg M, De Pitta M, Volman V, Berry H, Ben Jacob E. Nonlinear gap junctions enable long-distance propagation of pulsating calcium waves in astrocyte networks. PLoS Comput. Biol. 6(8) pii: e1000909 (2010).
62. Pelligrino DA, Vetri F, Xu HL. Purinergic mechanisms in gliovascular coupling. Semin. Cell Dev. Biol. 22(2), 229-236 (2011).
63. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7(1), 41-53 (2006). (Pubitemid 41828930)
64. Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58(9), 1094-1103 (2010).
65. Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J. Neurochem. 89(3), 788-800 (2004). (Pubitemid 38534163)
66. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J. Histochem. Cytochem. 54(10), 1159-1167 (2006). (Pubitemid 44434719)
67. Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an infammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol. 70(3), 1087-1098 (2006). (Pubitemid 44268466)
68. Hirrlinger J, Dringen R. Multidrug resistance protein 1-mediated export of glutathione and glutathione disulfde from brain astrocytes. Methods Enzymol. 400, 395-409 (2005). (Pubitemid 43052433)
69. Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R. The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfde from brain astrocytes. J. Neurochem. 97(2), 373-384 (2006).
70. Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells. J. Neurochem. 106(3), 1298-1313 (2008).
71. Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor a in cultured glial cells: involvement of nuclear factor-kB and c-Jun N-terminal kinase signaling pathways. Mol. Pharmacol. 77(4), 644-659 (2010).
72. Nies AT, Jedlitschky G, Konig J et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129(2), 349-360 (2004). (Pubitemid 39388854)
73. Bronger H, Konig J, Kopplow K et al. ABCC drug effux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 65(24), 11419-11428 (2005). (Pubitemid 41821699)
74. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 56(16), 1711-1735 (2008).
75. del Rio-Hortega P. Microglia. In: Cytology and Cellular Patholog y of the Nervous System. Penfeld W (Ed.). Hoecher, 481-584 (1932)
76. Speth C, Dierich MP, Sopper S. HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol. Immunol. 42(2), 213-228 (2005). (Pubitemid 39361450)
77. Lee G, Schlichter L, Bendayan M, Bendayan R. Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther. 299(1), 204-212 (2001). (Pubitemid 32905136)
78. Ronaldson PT, Lee G, Dallas S, Bendayan R. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm. Res. 21(5), 811-818 (2004). (Pubitemid 39011305)
79. Dallas S, Zhu X, Baruchel S, Schlichter L, Bendayan R. Functional expression of the multidrug resistance protein 1 in microglia. J. Pharmacol. Exp. Ther. 307(1), 282-290 (2003). (Pubitemid 37151919)
80. Dallas S, Schlichter L, Bendayan R. Multidrug resistance protein (MRP) 4-and MRP 5-mediated effux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J. Pharmacol. Exp. Ther. 309(3), 1221-1229 (2004). (Pubitemid 38669713)
81. Dore-Duffy P, Cleary K. Morphology and properties of pericytes. Methods Mol. Biol. 686, 49-68 (2011).
82. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J. Neurochem. 89(2), 503-513 (2004). (Pubitemid 38495998)
83. Gonul E, Duz B, Kahraman S, Kayali H, Kubar A, Timurkaynak E. Early pericyte response to brain hypoxia in cats: an ultrastructural study. Microvasc. Res. 64(1), 116-119 (2002). (Pubitemid 34713237)
84. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc. Res. 60(1), 55-69 (2000). (Pubitemid 30456828)
85. Armulik A, Genove G, Mae M et al. Pericytes regulate the blood-brain barrier. Nature 468(7323), 557-561 (2010).
86. Berezowski V, Landry C, Dehouck MP, Cecchelli R, Fenart L. Contribution of glial cells and pericytes to the mRNA profles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res. 1018(1), 1-9 (2004). (Pubitemid 38942854)
87. Ben Menachem E, Johansson BB, Svensson TH. Increased vulnerability of the blood-brain barrier to acute hypertension following depletion of brain noradrenaline. J. Neural Transm. 53(2-3), 159-167 (1982). (Pubitemid 12187307)
88. Cohen Z, Molinatti G, Hamel E. Astroglial and vascular interactions of noradrenaline terminals in the rat cerebral cortex. J. Cereb. Blood Flow Metab. 17(8), 894-904 (1997). (Pubitemid 27377644)
89. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 50(4), 335-362 (1996). (Pubitemid 27028536)
90. Vaucher E, Hamel E. Cholinergic basal forebrain neurons project to cortical microvessels in the rat: electron microscopic study with anterogradely transported Phaseolus vulgaris leucoagglutinin and choline acetyltransferase immunocytochemistry. J. Neurosci. 15(11), 7427-7441 (1995).
91. Tong XK, Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92(1), 163-175 (1999). (Pubitemid 29249027)
92. Vaucher E, Tong XK, Cholet N, Lantin S, Hamel E. GABA neurons provide a rich input to microvessels but not nitric oxide neurons in the rat cerebral cortex: a means for direct regulation of local cerebral blood fow. J. Comp Neurol. 421(2), 161-171 (2000). (Pubitemid 30246967)
93. Buxton RB, Frank LR. A model for the coupling between cerebral blood fow and oxygen metabolism during neural stimulation. J. Cereb. Blood Flow Metab. 17(1), 64-72 (1997). (Pubitemid 27014909)
94. Paemeleire K. The cellular basis of neurovascular metabolic coupling. Acta Neurol. Belg. 102(4), 153-157 (2002). (Pubitemid 36105237)
95. Vital SA, Terao S, Nagai M, Granger DN. Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 17(8), 641-649 (2010).
96. Cucullo L, Couraud PO, Weksler B et al. Immortalized human brain endothelial cells and fow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J. Cereb. Blood Flow Metab. 28(2), 312-328 (2008). (Pubitemid 351161282)
97. Sood RR, Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA. Early benefcial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 28(2), 431-438 (2008). (Pubitemid 351161291)
98. del Zoppo GJ. The neurovascular unit, matrix proteases, and innate infammation. Ann. NY Acad. Sci. 1207, 46-49 (2010).
99. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1), 11-25 (1992).
100. Tilling T, Engelbertz C, Decker S, Korte D, Huwel S, Galla HJ. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res. 310(1), 19-29 (2002).
101. Tilling T, Korte D, Hoheisel D, Galla HJ. Basement membrane proteins infuence brain capillary endothelial barrier function in vitro. J. Neurochem. 71(3), 1151-1157 (1998). (Pubitemid 28390269)
102. Savettieri G, Di L, I, Catania C et al. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport 11(5), 1081-1084 (2000). (Pubitemid 30235459)
103. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 429, 47-62 (1990). (Pubitemid 20327537)
104. Haskins J, Gu L, Wittchen ES, Hibbard J, Stevenson BR. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J. Cell Biol. 141(1), 199-208 (1998). (Pubitemid 28182652)
105. Del Maschio A, De Luigi A, Martin-Padura I et al. Leukocyte recruitment in the cerebrospinal fuid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J. Exp. Med 190(9), 1351-1356 (1999). (Pubitemid 29522218)
106. Dejana E, Lampugnani MG, Martinez-Estrada O, Bazzoni G. The molecular organization of endothelial junctions and their functional role in vascular morphogenesis and permeability. Int. J. Dev. Biol. 44(6), 743-748 (2000).
107. Yeung D, Manias JL, Stewart DJ, Nag S. Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathol. 115(6), 635-642 (2008).
108. Hoffman WH, Stamatovic SM, Andjelkovic AV. Infammatory mediators and blood-brain barrier disruption in fatal brain edema of diabetic ketoacidosis. Brain Res. 1254, 138-148 (2009).
109. Haarmann A, Deiss A, Prochaska J et al. Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown. PLoS One 5(10), e13568 (2010).
110. Furuse M, Hirase T, Itoh M et al. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 123(6 Pt 2), 1777-1788 (1993). (Pubitemid 24012933)
111. Hawkins BT, Abbruscato TJ, Egleton RD et al. Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res. 1027(1-2), 48-58 (2004). (Pubitemid 39370994)
112. Hirase T, Staddon JM, Saitou M et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci. 110 (Pt 14), 1603-1613 (1997). (Pubitemid 27338748)
113. McCarthy KM, Skare IB, Stankewich MC et al. Occludin is a functional component of the tight junction. J. Cell Sci. 109 (Pt 9), 2287-2298 (1996). (Pubitemid 26325491)
114. Lacaz-Vieira F, Jaeger MM, Farshori P, Kachar B. Small synthetic peptides homologous to segments of the frst external loop of occludin impair tight junction resealing. J. Membr. Biol. 168(3), 289-297 (1999). (Pubitemid 29177866)
115. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv. Drug Deliv. Rev. 57(6), 883-917 (2005). (Pubitemid 40488109)
116. Furuse M, Itoh M, Hirase T et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell Biol. 127(6 Pt 1), 1617-1626 (1994). (Pubitemid 24380900)
117. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 273(45), 29745-29753 (1998). (Pubitemid 28509986)
118. Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell Biol. 134(4), 1031-1049 (1996). (Pubitemid 26278226)
119. McCaffrey G, Staatz WD, Quigley CA et al. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J. Neurochem. 103(6), 2540-2555 (2007).
120. Saitou M, Furuse M, Sasaki H et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol. Biol. Cell 11(12), 4131-4142 (2000).
121. Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis T P. Blood-brain barrier tight junctions are altered during a 72-h exposure to l-carrageenan-induced infammatory pain. Am. J. Physiol. Heart Circ. Physiol. 283(4), H1531-H1537 (2002).
122. Brown RC, Davis TP. Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial cells. Biochem. Biophys. Res. Commun. 327(4), 1114-1123 (2005). (Pubitemid 40142636)
123. Nag S, Venugopalan R, Stewart DJ. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Acta Neuropathol. 114(5), 459-469 (2007). (Pubitemid 47521502)
124. Campos CR, Ocheltree SM, Hom S, Egleton RD, Davis T P. Nociceptive inhibition prevents infammatory pain induced changes in the blood-brain barrier. Brain Res. 1221, 6-13 (2008).
125. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA. Amyloid-b-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J. Cell Mol. Med 14(5), 1101-1112 (2010).
126. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and-2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141(7), 1539-1550 (1998). (Pubitemid 28309169)
127. Heiskala M, Peterson PA, Yang Y. The roles of claudin superfamily proteins in paracellular transport. Traffc 2(2), 93-98 (2001).
128. Furuse M, Sasaki H, Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol. 147(4), 891-903 (1999).
129. 2+-independent cell-adhesion activity of claudins, a family of integral membrane proteins localized at tight junctions. Curr. Biol. 9(18), 1035-1038 (1999). (Pubitemid 29456172)
130. Witt KA, Mark KS, Hom S, Davis TP. Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am. J. Physiol. Heart Circ. Physiol. 285(6), H2820-H2831 (2003). (Pubitemid 37443103)
131. Wolburg H, Wolburg-Buchholz K, Kraus J et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 105(6), 586-592 (2003). (Pubitemid 36798859)
132. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNFa on tight junction proteins in an in vitro model of the human blood-brain barrier. J. Physiol. 586(7), 1937-1949 (2008). (Pubitemid 351997519)
133. Wang P, Liu Y, Shang X, Xue Y. CRM197-induced blood-brain barrier permeability increase is mediated by upregulation of caveolin-1 protein. J. Mol. Neurosci. 43(3), 485-492 (2011).
134. Gonzalez-Mariscal L, Bnzos A, Avila-Flores A. MAGUK proteins: structure and role in the tight junction. Semin.Cell Dev. Biol. 11(4), 315-324 (2000). (Pubitemid 32066139)
135. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identifcation of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J. Cell Biol. 103(3), 755-766 (1986). (Pubitemid 17177325)
136. Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91(12), 2525-2538 (2002). (Pubitemid 35379411)
137. Fischer S, Wobben M, Marti HH, Renz D, Schaper W. Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc. Res. 63(1), 70-80 (2002). (Pubitemid 34971510)
138. Mark KS, Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am. J. Physiol. Heart Circ. Physiol. 282(4), H1485-H1494 (2002). (Pubitemid 34654903)
139. Gottardi CJ, Arpin M, Fanning AS, Louvard D. The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. Proc. Natl Acad. Sci. USA 93(20), 10779-10784 (1996). (Pubitemid 26333066)
140. Riesen FK, Rothen-Rutishauser B, Wunderli-Allenspach H. A ZO1-GFP fusion protein to study the dynamics of tight junctions in living cells. Histochem.Cell Biol. 117(4), 307-315 (2002). (Pubitemid 34985036)
141. Balda MS, Matter K. The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression. EMBO J. 19(9), 2024-2033 (2000). (Pubitemid 30237578)
142. Meyer TN, Schwesinger C, Denker BM. Zonula occludens-1 is a scaffolding protein for signaling molecules. Ga(12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells. J. Biol. Chem. 277(28), 24855-24858 (2002). (Pubitemid 34951784)
143. Gumbiner B, Lowenkopf T, Apatira D. Identifcation of a 160 kDa polypeptide that binds to the tight junction protein ZO-1. Proc. Natl Acad. Sci. USA 88(8), 3460-3464 (1991). (Pubitemid 21916641)
144. Bnzos A, Huerta M, Lopez-Bayghen E, Azuara E, Amerena J, Gonzalez-Mariscal L. The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells. Exp. Cell Res. 292(1), 51-66 (2004). (Pubitemid 38058263)
145. Islas S, Vega J, Ponce L, Gonzalez-Mariscal L. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp. Cell Res. 274(1), 138-148 (2002).
146. Traweger A, Fuchs R, Krizbai IA, Weiger TM, Bauer HC, Bauer H. The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B. J. Biol. Chem. 278(4), 2692-2700 (2003). (Pubitemid 36801350)
147. Umeda K, Matsui T, Nakayama M et al. Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J. Biol. Chem. 279(43), 44785-44794 (2004). (Pubitemid 39430889)
148. Takenaga Y, Takagi N, Murotomi K, Tanonaka K, Takeo S. Inhibition of Src activity decreases tyrosine phosphorylation of occludin in brain capillaries and attenuates increase in permeability of the blood-brain barrier after transient focal cerebral ischemia. J. Cereb.Blood Flow Metab. 29(6), 1099-1108 (2009).
149. Bangsow T, Baumann E, Bangsow C et al. The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J. Cereb.Blood Flow Metab. 28(6), 1249-1260 (2008). (Pubitemid 351733349)
150. Citi S, Sabanay H, Kendrick-Jones J, Geiger B. Cingulin: characterization and localization. J. Cell Sci. 93 (Pt 1), 107-122 (1989). (Pubitemid 19148928)
151. Yamamoto T, Harada N, Kawano Y, Taya S, Kaibuchi K. In vivo interaction of AF-6 with activated Ras and ZO-1. Biochem. Biophys. Res. Commun. 259(1), 103-107 (1999). (Pubitemid 29264001)
152. Zhong Y, Enomoto K, Isomura H et al. Localization of the 7H6 antigen at tight junctions correlates with the paracellular barrier function of MDCK cells. Exp. Cell Res. 214(2), 614-620 (1994). (Pubitemid 24310820)
153. Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics. J. Cereb. Blood Flow Metab. 21(1), 61-68 (2001). (Pubitemid 32016840)
154. Li JY, Boado RJ, Pardridge WM. Rat blood-brain barrier genomics. II. J. Cereb. Blood Flow Metab. 22(11), 1319-1326 (2002). (Pubitemid 35285089)
155. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204(3), 216-237 (2005). (Pubitemid 40552845)
156. Robey RW, To KK, Polgar O et al. ABCG2: a perspective. Adv. Drug Deliv. Rev. 61(1), 3-13 (2009).
157. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455(1), 152-162 (1976).
158. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic ana lysis of the multidrug transporter. Annu. Rev. Genet. 29, 607-649 (1995). (Pubitemid 26005354)
159. Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem.J. 326 (Pt 2), 539-544 (1997). (Pubitemid 27417234)
160. Virgintino D, Robertson D, Errede M et al. Expression of P-glycoprotein in human cerebral cortex microvessels. J. Histochem. Cytochem. 50(12), 1671-1676 (2002). (Pubitemid 36078133)
161. Golden PL, Pardridge WM. P-glycoprotein on astrocyte foot processes of unfxed isolated human brain capillaries. Brain Res. 819(1-2), 143-146 (1999). (Pubitemid 29225465)
162. Schlachetzki F, Pardridge WM. P-glycoprotein and caveolin-1a in endothelium and astrocytes of primate brain. Neuroreport 14(16), 2041-2046 (2003).
163. Sharom FJ. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem. Cell Biol. 84(6), 979-992 (2006). (Pubitemid 46450697)
164. Letrent SP, Polli J W, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 58(6), 951-957 (1999). (Pubitemid 29361461)
165. Cisternino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-defcient mice. Pharm. Res. 18(2), 183-190 (2001). (Pubitemid 32592598)
166. Dagenais C, Zong J, Ducharme J, Pollack GM. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm. Res. 18(7), 957-963 (2001). (Pubitemid 32799940)
167. Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67(2), 269-276 (2004). (Pubitemid 38112757)
168. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ. Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab. Dispos. 29(7), 954-956 (2001). (Pubitemid 32605909)
169. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)-and (S)-enantiomers is greatly increased by P-glycoprotein defciency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl.) 173(1-2), 132-138 (2004). (Pubitemid 38591157)
170. Bauer B, Yang X, Hartz AM et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70(4), 1212-1219 (2006). (Pubitemid 44435972)
171. Ortega I, Rodriguez M, Suarez E, Perez-Ruixo JJ, Calvo R. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar. Pharm. Res. 24(7), 1299-1308 (2007). (Pubitemid 46870595)
172. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13(7), 905-915 (2010).
173. Hamabe W, Maeda T, Fukazawa Y et al. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol. Biochem. Behav. 85(3), 629-636 (2006). (Pubitemid 46097074)
174. Kalvass JC, Olson ER, Pollack GM. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-defcient mice: P-glycoprotein effux alters alfentanil brain disposition and antinociception. Drug Metab. Dispos. 35(3), 455-459 (2007). (Pubitemid 46333909)
175. Dagenais C, Ducharme J, Pollack GM. Uptake and effux of the peptidic d-opioid receptor agonist. Neurosci. Lett. 301(3), 155-158 (2001).
176. Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the effux drug transporter P-glycoprotein. Anesthesiology 96(4), 913-920 (2002). (Pubitemid 34266685)
177. Bostrom E, Simonsson US, Hammarlund-Udenaes M. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J. Pharm. Sci. 94(5), 1060-1066 (2005). (Pubitemid 40780772)
178. Hassan HE, Myers AL, Coop A, Eddington ND. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J. Pharm. Sci. 98(12), 4928-4940 (2009).
179. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58(6), 1357-1367 (2000).
180. Leggas M, Adachi M, Scheffer GL et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell Biol. 24(17), 7612-7621 (2004). (Pubitemid 39121487)
181. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J. Pharmacol. Exp. Ther. 311(2), 449-455 (2004). (Pubitemid 39391528)
182. Bandler PE, Westlake CJ, Grant CE, Cole SP, Deeley RG. Identifcation of regions required for apical membrane localization of human multidrug resistance protein 2. Mol. Pharmacol. 74(1), 9-19 (2008). (Pubitemid 351872154)
183. van de WK, Zelcer N, Kuil A et al. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol. Pharmacol. 72(2), 387-394 (2007). (Pubitemid 47124119)
184. Hasegawa Y, Kishimoto S, Takahashi H, Inotsume N, Takeuchi Y, Fukushima S. Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis. J. Pharm. Pharmacol. 61(9), 1205-1210 (2009).
185. Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML. Morphine analgesia in cancer pain: role of the glucuronides. J. Opioid. Manag. 1(2), 83-90 (2005).
186. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin. Pharmacol. Ther. 68(6), 667-676 (2000). (Pubitemid 32059993)
187. Schuetz JD, Connelly MC, Sun D et al. MRP4: a previously unidentifed factor in resistance to nucleoside-based antiviral drugs. Nat. Med 5(9), 1048-1051 (1999). (Pubitemid 29439577)
188. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275(39), 30069-30074 (2000).
189. Clemente MI, Alvarez S, Serramia MJ et al. Non-steroidal anti-infammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. Antivir. Ther. 14(8), 1101-1111 (2009).
190. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13(16), 2059-2063 (2002). (Pubitemid 36005925)
191. Hori S, Ohtsuki S, Tachikawa M et al. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J. Neurochem. 90(3), 526-536 (2004). (Pubitemid 38989383)
192. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of effux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J. Pharmacol. Exp. Ther. 312(1), 44-52 (2005). (Pubitemid 40096451)
193. van Herwaarden AE, Jonker JW, Wagenaar E et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63(19), 6447-6452 (2003). (Pubitemid 37255195)
194. Zhao R, Raub TJ, Sawada GA et al. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate effux at the blood-brain barrier. Drug Metab. Dispos. 37(6), 1251-1258 (2009).
195. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res. 13(21), 6440-6449 (2007). (Pubitemid 350075034)
196. ®), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab. Dispos. 37(5), 946-955 (2009).
197. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. 336(1), 223-233 (2011).
198. Sugiura T, Kato Y, Tsuji A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J. Control Release 116(2), 238-246 (2006). (Pubitemid 44854272)
199. Kusuhara H, Sugiyama Y. Active effux across the blood-brain barrier: role of the solute carrier family. NeuroRx. 2(1), 73-85 (2005). (Pubitemid 40128028)
200. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classifcation as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pfugers Arch. 447(5), 653-665 (2004). (Pubitemid 38241451)
201. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294(1), 73-79 (2000). (Pubitemid 30434672)
202. Elkiweri IA, Zhang YL, Christians U, Ng KY, Tissot van Patot MC, Henthorn TK. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth. Analg. 108(1), 149-159 (2009).
203. Sugiyama D, Kusuhara H, Taniguchi H et al. Functional characterization of rat brain-specifc organic anion transporter (Oatp14) at the blood-brain barrier: high affnity transporter for thyroxine. J. Biol. Chem. 278(44), 43489-43495 (2003). (Pubitemid 37345972)
204. Taogoshi T, Nomura A, Murakami T, Nagai J, Takano M. Transport of prostaglandin E1 across the blood-brain barrier in rats. J. Pharm.Pharmacol. 57(1), 61-66 (2005). (Pubitemid 40030103)
205. Chu C, Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics and cloning of a novel organic anion transporter. J. Cereb. Blood Flow Metab. 28(2), 291-301 (2008). (Pubitemid 351161295)
206. Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP. Infammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am. J. Physiol. Heart Circ. Physiol. 280(3), H1241-H1248 (2001).
207. Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic infammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am. J. Physiol. Heart Circ. Physiol. 289(2), H738-H743 (2005). (Pubitemid 41129391)
208. Huber JD, Campos CR, Mark KS, Davis TP. Alterations in blood-brain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced infammatory pain. Am. J. Physiol. Heart Circ. Physiol. 290(2), H732-H740 (2006).
209. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. Quantifcation of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res.Brain Res. Protoc. 8(2), 126-131 (2001). (Pubitemid 32973928)
210. Brooks TA, Ocheltree SM, Seelbach MJ et al. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic infammatory pain. Brain Res. 1120(1), 172-182 (2006). (Pubitemid 44648013)
211. Xie R, Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm. Res. 15(4), 570-575 (1998). (Pubitemid 28214950)
212. Fischer W, Bernhagen J, Neubert RH, Brandsch M. Uptake of codeine into intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells. Eur. J. Pharm. Sci. 41(1), 31-42 (2010).
213. Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7(4), 257-265 (2007). (Pubitemid 47202488)
214. Lotsch J, Skarke C, Schmidt H et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin. Pharmacol. Ther. 79(1), 35-48 (2006). (Pubitemid 43069577)
215. King CD, Rios GR, Assouline JA, Tephly TR. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identifcation of 5-hydroxytryptamine as a substrate. Arch. Biochem. Biophys. 365(1), 156-162 (1999). (Pubitemid 29394261)
216. Pepper MS. Transforming growth factor-b: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8(1), 21-43 (1997). (Pubitemid 27214687)
217. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature 425(6958), 577-584 (2003). (Pubitemid 37280136)
218. Lebrin F, Deckers M, Bertolino P, ten Dijke P. TGF-b receptor function in the endothelium. Cardiovasc. Res. 65(3), 599-608 (2005).
219. Wu X, Ma J, Han JD, Wang N, Chen YG. Distinct regulation of gene expression in human endothelial cells by TGF-b and its receptors. Microvasc. Res. 71(1), 12-19 (2006). (Pubitemid 43175844)
220. Seki T, Yun J, Oh SP. Arterial endothelium-specifc activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ. Res. 93(7), 682-689 (2003). (Pubitemid 37222165)
221. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-b type I receptors. EMBO J. 21(7), 1743-1753 (2002). (Pubitemid 34614630)
222. Watabe T, Nishihara A, Mishima K et al. TGF-b receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J. Cell Biol. 163(6), 1303-1311 (2003). (Pubitemid 38032091)
223. Ishihara H, Kubota H, Lindberg RL et al. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor b2 involves matrix metalloproteinases and tight junction proteins. J. Neuropathol. Exp. Neurol. 67(5), 435-448 (2008). (Pubitemid 351653535)
224. Inman GJ, Nicolas FJ, Callahan JF et al. SB-431542 is a potent and specifc inhibitor of transforming growth factor-b superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62(1), 65-74 (2002). (Pubitemid 34680517)
225. Lu P, Gonzales C, Chen Y et al. CNS penetration of small molecules following local infammation, widespread systemic infammation or direct injury to the nervous system. Life Sci. 85(11-12), 450-456 (2009).
226. Nagaraja TN, Keenan KA, Fenstermacher JD, Knight RA. Acute leakage patterns of fuorescent plasma fow markers after transient focal cerebral ischemia suggest large openings in blood-brain barrier. Microcirculation 15(1), 1-14 (2008).
227. Strbian D, Durukan A, Pitkonen M et al. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 153(1), 175-181 (2008).
228. Salvemini D, Doyle TM, Cuzzocrea S. Superoxide, peroxynitrite and oxidative/nitrative stress in infammation. Biochem. Soc. Trans. 34(Pt 5), 965-970 (2006). (Pubitemid 44796461)
229. Wang ZQ, Porreca F, Cuzzocrea S et al. A newly identifed role for superoxide in infammatory pain. J. Pharmacol. Exp. Ther. 309(3), 869-878 (2004). (Pubitemid 38669673)
230. Khattab MM. TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite-and superoxide anion-enhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur. J. Pharmacol. 548(1-3), 167-173 (2006). (Pubitemid 44397019)
231. van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 46(10), 1569-1580 (2005). (Pubitemid 44921930)
232. Hayashi K, Pu H, Tian J et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J. Neurochem. 93(5), 1231-1241 (2005). (Pubitemid 40776576)
233. Hayashi K, Pu H, Andras IE et al. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J. Cereb. Blood Flow Metab. 26(8), 1052-1065 (2006). (Pubitemid 44134076)
234. Pekcec A, Unkruer B, Stein V et al. Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res. 83(2-3), 144-151 (2009).
235. Hartmann G, Cheung AK, Piquette-Miller M. Infammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303(1), 273-281 (2002).
236. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of mdr1a expression in the brain and liver during CNS infammation alters the in vivo disposition of digoxin. Br. J. Pharmacol. 139(1), 35-48 (2003). (Pubitemid 36645306)
237. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-a and lipopolysaccharide. Mol. Pharmacol. 69(2), 462-470 (2006). (Pubitemid 43121943)
238. Salkeni MA, Lynch JL, Otamis-Price T, Banks WA. Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin-and nitric oxide-independent pathways. J. Neuroimmune. Pharmacol. 4(2), 276-282 (2009).
239. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fxation and staining variables. J. Histochem. Cytochem. 53(4), 517-531 (2005). (Pubitemid 40463506)
240. Ossipov MH, Kovelowski CJ, Porreca F. The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw infammation is blocked by naltrindole, a selective d-opioid antagonist. Neurosci. Lett. 184(3), 173-176 (1995).
241. Cui YJ, Cheng X, Weaver YM, Klaassen CD. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab. Dispos. 37(1), 203-210 (2009).
242. Noe B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multispecifc organic anion and cardiac glycoside transporter from rat brain. Proc. Natl Acad. Sci. USA 94(19), 10346-10350 (1997).
243. Egleton RD, Davis TP. Transport of the d-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis. J. Pharm. Sci. 88(4), 392-397 (1999). (Pubitemid 29180762)
244. Sharom FJ, Yu X, Lu P et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affnity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem. Pharmacol. 58(4), 571-586 (1999). (Pubitemid 29296877)
245. Ronaldson PT, Tran CS, Rasaiah VPA, Bendayan R. Increased functional expression of multidrug resistance protein 1 (Mrp1) in cultured glial cells treated with the HIV-1 viral envelope protein gp120 and cytokines. Can. J. Infect. Dis. 18, 13B (2007).
246. Dohgu S, Yamauchi A, Takata F et al. Transforming growth factor-b1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol. Neurobiol. 24(3), 491-497 (2004). (Pubitemid 38988077)
247. Levy DE, Lee CK. What does STAT3 do? J. Clin. Invest 109(9), 1143-1148 (2002). (Pubitemid 34496591)
248. Dreuw A, Hermanns HM, Heise R et al. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fbroblasts. J. Invest Dermatol. 124(1), 28-37 (2005). (Pubitemid 40100945)
249. Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29(4), 490-496 (2008). (Pubitemid 351416803)
250. Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev. 35(4), 305-317 (2003). (Pubitemid 38018109)
251. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 66(3), 413-419 (2004). (Pubitemid 39329239)
252. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47(5), 566-578 (2007). (Pubitemid 46632158)
253. Lombardo L, Pellitteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res. 5(2), 82-92 (2008). (Pubitemid 351838572)
254. Narang VS, Fraga C, Kumar N et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am. J. Physiol. Cell Physiol. 295(2), C440-C450 (2008). (Pubitemid 352755780)
255. Zastre JA, Chan GN, Ronaldson PT et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87(4), 1023-1036 (2009).
256. Wang X, Sykes DB, Miller DS. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic effux transporters at the blood-brain barrier. Mol. Pharmacol. 78(3), 376-383 (2010).
257. Cheng X, Maher J, Dieter MZ, Klaassen CD. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 33(9), 1276-1282 (2005). (Pubitemid 41196968)
258. Stedman CA, Liddle C, Coulter SA et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl Acad. Sci. USA 102(6), 2063-2068 (2005). (Pubitemid 40262012)
259. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab. Dispos. 32(9), 1008-1014 (2004). (Pubitemid 39096062)
260. Stein A, Yassouridis A, Szopko C, Helmke K, Stein C. Intraarticular morphine versus dexamethasone in chronic arthritis. Pain 83(3), 525-532 (1999).
261. Kardash KJ, Sarrazin F, Tessler MJ, Velly AM. Single-dose dexamethasone reduces dynamic pain after total hip arthroplasty. Anesth. Analg. 106(4), 1253-1257 (2008). (Pubitemid 351450555)
262. Pieretti S, Di Giannuario A, Domenici MR et al. Dexamethasone-induced selective inhibition of the central μ-opioid receptor: functional in vivo and in vitro evidence in rodents. Br. J. Pharmacol. 113(4), 1416-1422 (1994). (Pubitemid 24364429)
263. Capasso A, Loizzo A. Functional interference of dexamethasone on some morphine effects: hypothesis for the steroid-opioid interaction. Recent Pat. CNS Drug Discov. 3(2), 138-150 (2008).
264. Oak S, Choi BH. The effects of glutathione glycoside in acetaminophen-induced liver cell necrosis. Exp. Mol. Pathol. 65(1), 15-24 (1998). (Pubitemid 28246507)
265. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specifcity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 290(4), G640-G649 (2006).
266. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298(5592), 422-424 (2002). (Pubitemid 35176352)
267. Yamamoto T, Nair P, Ma SW et al. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Bioorg. Med. Chem. 17(20), 7337-7343 (2009).
268. Largent-Milnes TM, Yamamoto T, Nair P et al. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br. J. Pharmacol. 161(5), 986-1001 (2010).